Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
Nyxoah reported preliminary Q3 2026 global net revenue of approximately €9.2 million, up 19% sequentially, with U.S. net revenue of €6.7 million up 29% sequentially. The company cut full-year 2026 revenue guidance to €33-35 million from €36-40 million previously, while pointing to strong commercial indicators: 342 trained U.S. surgeons, 233 active high-volume accounts, and 447 patients under prior authorization entering Q4.
Key figures
- Revenue
- €9.2 million
- Drug Name
- Genio
- Guidance
- FY2026 global net revenue €33 million to €35 million, lowered from €36 million to €40 million
- Phase Of Trial
- pivotal (ACCCESS study)
- New accounts q3
- 53
- New surgeons q3
- 80
- Us net revenue q3
- €6.7 million
- Sequential growth us
- 29%
- Surgeons trained total
- 342
- Ahi responder rate 12mo
- 77.2%
- Sequential growth global
- 19%
- Cash and financial assets
- €77.0 million
- Active high volume accounts
- 233
- Patients under prior authorization
- 447
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.